Pfizer's Coming for AbbVie's Market Share. ... (now that Humira is seeing competition from generics as a result of going over the patent cliff in the U.S. this year).

Pfizer’s revenue rose at an average annual rate of 25.6% from $41.7 billion in 2020 to $58.5 billion in 2023, while AbbVie’s revenue grew at an average rate of 6.5% from $45.8 billion to $54.3 ...

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune ...

The stock's fall snapped a three-day winning streak.

Competition in the Oncology Space. Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Pfizer PFE.. For AstraZeneca, oncology sales now account for nearly 41% of total ...

AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces ...

AbbVie’s CGRP pill Ubrelvy was approved in 2019 to treat migraine. It generated $680 million in sales last year for an increase of 23% on 2021. Lilly’s oral CGRP Reyvow was endorsed the same year.

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.